Lin Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lin Fan has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
Wenwen Sun
Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai Clinic and Research Center of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai, People's Republic of China
16 shared publications- Jianping Xie
Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Southwest University, Chongqing, China
11 shared publications Shao-Jun Zhang
Department of Tuberculosis, Shanghai Pulmonary Hospital, Shanghai Clinic and Research Center of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Tongji University School of Medicine, Shanghai, China
7 shared publicationsWen-Wen Sun
Department of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai Clinical Research Center for Tuberculosis, Shanghai Key Lab of Tuberculosis, Shanghai, China
7 shared publications- Zhemin Zhang
Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China
7 shared publications Zhengwei Dong
Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
7 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9848
Preclinical Study on Novel Treatment Regimen for Elderly Patients with Drug-Sensitive Pulmonary Tuberculosis
Treatment for elderly patients with pulmonary tuberculosis (PTB) is challenging due to poor efficacy and tolerance. The aim of this study is to preliminarily screen candidate regimens for elderly patients with drug-sensitive PTB. Candidate regimens were initially screened using the artificial-intelligence-enabled phenotypic response surface (AI-PRS) platform and in vitro experiments. The hepatorenal cytotoxicity of drug combinations was assessed with HEK293T and THLE-2 cells. In the in vivo validation stage, aged mice with airway Mycobacterium tuberculosis (Mtb) infection received the novel regimens by oral gavage for 4 weeks, while isoniazid (H)/rifampicin (R)/ethambutol (E)/pyrazinamide (Z) served as the standard regimen control. Hepatorenal function was monitored during the treatment to assess drug safety, and pathological HE staining was also performed to evaluate liver and kidney damage. Bacterial loads in the lungs and spleens were evaluated using colony-forming unit (CFU) assays. After three rounds of AI-PRS analysis and MIC screening in vitro, three optimized treatment regimens were identified including delamanid (Dlm)/bedaquiline (Bdq)/pretomanid (Pa) combined with rifapentine (Rpt), pasiniazid (PAS-H) and levofloxacin (Lfx). After validation with an experiment on aged mice, the Bdq-containing regimen resulted in the mildest pulmonary inflammation and the lowest bacterial loads in lungs and spleens. The bacterial burden was similar between Bdq- and Dlm-containing regimens, which presented stronger bactericidal activity over the HREZ regimen. Regarding drug safety evaluation, the Bdq-containing regimen showed no marked hepatotoxicity and nephrotoxicity in our preclinical models, while other regimens showed variable abnormalities in serum biochemical indices. The Bdq/Lfx/PAS-H/Rpt regimen presented high efficacy and more favorable safety in aged mice compared with the standard regimen, considered as a promising preclinical candidate for elderly patients with drug-sensitive TB and deserving of further clinical trials for evaluation.
- 3 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9848
Open AccessPreclinical Study on Novel Treatment Regimen for Elderly Patients with Drug-Sensitive Pulmonary Tuberculosis
Treatment for elderly patients with pulmonary tuberculosis (PTB) is challenging due to poor efficacy and tolerance. The aim of this study is to preliminarily screen candidate regimens for elderly patients with drug-sensitive PTB. Candidate regimens were initially screened using the artificial-intelligence-enabled phenotypic response surface (AI-PRS) platform and in vitro experiments. The hepatorenal cytotoxicity of drug combinations was assessed with HEK293T and THLE-2 cells. In the in vivo validation stage, aged mice with airway Mycobacterium tuberculosis (Mtb) infection received the novel regimens by oral gavage for 4 weeks, while isoniazid (H)/rifampicin (R)/ethambutol (E)/pyrazinamide (Z) served as the standard regimen control. Hepatorenal function was monitored during the treatment to assess drug safety, and pathological HE staining was also performed to evaluate liver and kidney damage. Bacterial loads in the lungs and spleens were evaluated using colony-forming unit (CFU) assays. After three rounds of AI-PRS analysis and MIC screening in vitro, three optimized treatment regimens were identified including delamanid (Dlm)/bedaquiline (Bdq)/pretomanid (Pa) combined with rifapentine (Rpt), pasiniazid (PAS-H) and levofloxacin (Lfx). After validation with an experiment on aged mice, the Bdq-containing regimen resulted in the mildest pulmonary inflammation and the lowest bacterial loads in lungs and spleens. The bacterial burden was similar between Bdq- and Dlm-containing regimens, which presented stronger bactericidal activity over the HREZ regimen. Regarding drug safety evaluation, the Bdq-containing regimen showed no marked hepatotoxicity and nephrotoxicity in our preclinical models, while other regimens showed variable abnormalities in serum biochemical indices. The Bdq/Lfx/PAS-H/Rpt regimen presented high efficacy and more favorable safety in aged mice compared with the standard regimen, considered as a promising preclinical candidate for elderly patients with drug-sensitive TB and deserving of further clinical trials for evaluation.
- Open Access
- 28 October 2026
- Published by Springer Nature in Inflammation
Altered Lysine Lactylation Modulates host Defense Against Tuberculosis via Mitochondrial Protein Regulation
- 28 October 2026
- Published by Springer Nature in Inflammation
Open AccessAltered Lysine Lactylation Modulates host Defense Against Tuberculosis via Mitochondrial Protein Regulation
- Open Access
- 22 January 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (3)
Mycobacterial non-homologous end joining is required for antiphage defense
In the ongoing arms race with phages, bacteria have evolved diverse defense systems, such as CRISPR–Cas and restriction–modification systems. The DNA double-strand break repair system represents a core mechanism for maintaining genomic integrity and is vital for cell survival. However, it remains unknown whether and how these repair systems contribute to phage resistance. This study systematically investigates the role of the non-homologous end joining (NHEJ) during phage infection in Mycobacterium smegmatis. We found that NHEJ deficiency compromises host resistance to phage SWU1, as evidenced by increased plaque counts and reduced bacterial survival. Mechanistically, phages exploit host NHEJ for genomic repair; however, the error-prone nature of NHEJ leads to imperfect repair at phage cos sites, thereby blocking replication. The host modulates the balance between NHEJ and homologous recombination (HR) to control repair fidelity: NHEJ loss shifts the balance toward high-fidelity HR, which in turn promotes phage survival. Furthermore, NHEJ deficiency exacerbates infection-induced oxidative stress, leading to a compromise in bacterial viability. Our findings reveal the multifaceted functions of NHEJ in mycobacterium–phage interactions and provide new insights into how DNA repair systems shape antiphage defense and coevolution.
- 22 January 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (3)
Open AccessMycobacterial non-homologous end joining is required for antiphage defense
In the ongoing arms race with phages, bacteria have evolved diverse defense systems, such as CRISPR–Cas and restriction–modification systems. The DNA double-strand break repair system represents a core mechanism for maintaining genomic integrity and is vital for cell survival. However, it remains unknown whether and how these repair systems contribute to phage resistance. This study systematically investigates the role of the non-homologous end joining (NHEJ) during phage infection in Mycobacterium smegmatis. We found that NHEJ deficiency compromises host resistance to phage SWU1, as evidenced by increased plaque counts and reduced bacterial survival. Mechanistically, phages exploit host NHEJ for genomic repair; however, the error-prone nature of NHEJ leads to imperfect repair at phage cos sites, thereby blocking replication. The host modulates the balance between NHEJ and homologous recombination (HR) to control repair fidelity: NHEJ loss shifts the balance toward high-fidelity HR, which in turn promotes phage survival. Furthermore, NHEJ deficiency exacerbates infection-induced oxidative stress, leading to a compromise in bacterial viability. Our findings reveal the multifaceted functions of NHEJ in mycobacterium–phage interactions and provide new insights into how DNA repair systems shape antiphage defense and coevolution.
- 27 June 2025
- Published by Elsevier in Clinical Radiology
- Vol. 88, 107004
The diagnostic model from semi-supervised cross modality transformation improved the distinguished ability of X-rays for pulmonary tuberculosis
- 27 June 2025
- Published by Elsevier in Clinical Radiology
- Vol. 88, 107004
The diagnostic model from semi-supervised cross modality transformation improved the distinguished ability of X-rays for pulmonary tuberculosis
- Open Access
- 23 August 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-10
Mycobacterium smegmatis MfpC is a GEF that regulates mfpA translationally to alter the fluoroquinolone efficacy
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a serious threat to global public health. Fluoroquinolones (FQs) are effective against M. tuberculosis; however, resistant strains have limited their efficacy. Mycobacterium fluoroquinolone resistance protein A (MfpA) confers intrinsic resistance to FQs; however, its regulatory mechanisms remain largely unknown. Using M. smegmatis as a model, we investigated whether MfpC is necessary for FQ susceptibility. MfpC mutants were sensitive to moxifloxacin, indicating that MfpC is involved in FQ susceptibility. By testing the mfpC inactivation phenotype in different mutants and using mycobacterial protein fragment complementation, we demonstrated that the function of MfpC depends on its interactions with MfpB. Guanine nucleotide exchange assays and site-directed mutagenesis confirmed that MfpC acts as a guanine nucleotide exchange factor to regulate MfpB. We propose that MfpB influences MfpA at the translational level. In summary, we reveal the role of MfpC in regulating the function of MfpA in FQ resistance.
- 23 August 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-10
Open AccessMycobacterium smegmatis MfpC is a GEF that regulates mfpA translationally to alter the fluoroquinolone efficacy
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a serious threat to global public health. Fluoroquinolones (FQs) are effective against M. tuberculosis; however, resistant strains have limited their efficacy. Mycobacterium fluoroquinolone resistance protein A (MfpA) confers intrinsic resistance to FQs; however, its regulatory mechanisms remain largely unknown. Using M. smegmatis as a model, we investigated whether MfpC is necessary for FQ susceptibility. MfpC mutants were sensitive to moxifloxacin, indicating that MfpC is involved in FQ susceptibility. By testing the mfpC inactivation phenotype in different mutants and using mycobacterial protein fragment complementation, we demonstrated that the function of MfpC depends on its interactions with MfpB. Guanine nucleotide exchange assays and site-directed mutagenesis confirmed that MfpC acts as a guanine nucleotide exchange factor to regulate MfpB. We propose that MfpB influences MfpA at the translational level. In summary, we reveal the role of MfpC in regulating the function of MfpA in FQ resistance.
- 22 January 2024
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 22 (5) , 353-363
Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China
ObjectiveWith the change in drug-resistant pattern, MDR/RR-TB was faced with underlying changes in regimens. A multi-center, large-scale, retrospective study performed aims to provide a recommendation of drug selection on optimization of outcome for the patients.MethodThe study was conducted in six TB-specialized hospitals in China. Patients were included from 2018-2021 and followed up throughout the treatment. Using a multivarariable and propensity score-matched logistic regression analysis, we evaluated associations between outcomes and drug use, as well as clinical characteritics.ResultsOf 3112 patients, 74.29% had treatment sucess, 14.52% lost to follow-up, 9.67% failure, and 1.51% died. Treatment success was positively associated with Bedaquiline(Bdq), Linezolid(Lzd), and Cycloserin(Cs). Capreomycin(Cm) increased the risk of unfavorable outcomes. other drugs such as Amikacin(Amk) and clofazimine had no significant effect on outcomes. If isolates were susceptible to fluoroquinolones(FQs), FQs could decrease the risk of unfavorable outcomes.ConclusionsThe recommendation order for the treatment of MDR/RR-TB is Bdq, Lzd, and Cs. FQs were decreased in use intensity. Injection drugs, whether Amk or Cm, are not recommended.
- 22 January 2024
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 22 (5) , 353-363
Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China
ObjectiveWith the change in drug-resistant pattern, MDR/RR-TB was faced with underlying changes in regimens. A multi-center, large-scale, retrospective study performed aims to provide a recommendation of drug selection on optimization of outcome for the patients.MethodThe study was conducted in six TB-specialized hospitals in China. Patients were included from 2018-2021 and followed up throughout the treatment. Using a multivarariable and propensity score-matched logistic regression analysis, we evaluated associations between outcomes and drug use, as well as clinical characteritics.ResultsOf 3112 patients, 74.29% had treatment sucess, 14.52% lost to follow-up, 9.67% failure, and 1.51% died. Treatment success was positively associated with Bedaquiline(Bdq), Linezolid(Lzd), and Cycloserin(Cs). Capreomycin(Cm) increased the risk of unfavorable outcomes. other drugs such as Amikacin(Amk) and clofazimine had no significant effect on outcomes. If isolates were susceptible to fluoroquinolones(FQs), FQs could decrease the risk of unfavorable outcomes.ConclusionsThe recommendation order for the treatment of MDR/RR-TB is Bdq, Lzd, and Cs. FQs were decreased in use intensity. Injection drugs, whether Amk or Cm, are not recommended.
- Open Access
- 1 August 2023
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 5055-5064
The Safety and Efficacy of Prolonged Use of Bedaquiline for the Treatment of Patients with Pulmonary Multi-Drug Resistant/Rifampin-Resistant Tuberculosis: A Prospective, Cohort Study in China
Objective: To evaluate the safety, tolerability, and efficacy of prolonged bedaquiline (Bdq) treatment in patients with multi-drug/rifampin-resistant tuberculosis (MDR/RR-TB). Methods: This prospective cohort study was performed from August 2018 to August 2021. Patients diagnosed with MDR/RR-TB who met the inclusion criteria were prospectively included. Patients were treated with individual regimens of 18– 20 months containing Bdq for six months or a prolonged course of nine or 12 months according to treatment demands, and the efficacy and safety with a different course of Bdq-containing regimens were compared and evaluated. Results: A total of 159 MDR/RR-TB patients were included in the study, including 96 cases with six months of Bdq, 50 cases with nine months of Bdq, and 13 patients with 12 months of Bdq. The treatment success rates were 89.6%, 90%, and 84.6% in Bdq at six months, nine months, and 12 months, respectively, which were not statistically different (P = 0.85). The main adverse events (AEs) were anemia, thrombocytopenia, and liver dysfunction in all patients, with no significant difference among the three groups. Patients who had fewer drugs chosen, disseminated lesions or lesions that were slowly absorbed, and severe cavities were the common reasons for prolonged use of Bdq. Conclusion: Prolonged course use of Bdq from six months to 12 months clinically proved to be safe and efficient, and patients with severe or disseminated lesions had the chance to prolong the use of Bdq for more than six months to achieve optimal treatment outcomes.
- 1 August 2023
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 5055-5064
Open AccessThe Safety and Efficacy of Prolonged Use of Bedaquiline for the Treatment of Patients with Pulmonary Multi-Drug Resistant/Rifampin-Resistant Tuberculosis: A Prospective, Cohort Study in China
Objective: To evaluate the safety, tolerability, and efficacy of prolonged bedaquiline (Bdq) treatment in patients with multi-drug/rifampin-resistant tuberculosis (MDR/RR-TB). Methods: This prospective cohort study was performed from August 2018 to August 2021. Patients diagnosed with MDR/RR-TB who met the inclusion criteria were prospectively included. Patients were treated with individual regimens of 18– 20 months containing Bdq for six months or a prolonged course of nine or 12 months according to treatment demands, and the efficacy and safety with a different course of Bdq-containing regimens were compared and evaluated. Results: A total of 159 MDR/RR-TB patients were included in the study, including 96 cases with six months of Bdq, 50 cases with nine months of Bdq, and 13 patients with 12 months of Bdq. The treatment success rates were 89.6%, 90%, and 84.6% in Bdq at six months, nine months, and 12 months, respectively, which were not statistically different (P = 0.85). The main adverse events (AEs) were anemia, thrombocytopenia, and liver dysfunction in all patients, with no significant difference among the three groups. Patients who had fewer drugs chosen, disseminated lesions or lesions that were slowly absorbed, and severe cavities were the common reasons for prolonged use of Bdq. Conclusion: Prolonged course use of Bdq from six months to 12 months clinically proved to be safe and efficient, and patients with severe or disseminated lesions had the chance to prolong the use of Bdq for more than six months to achieve optimal treatment outcomes.